Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

被引:0
作者
Michael F. Egan
Yuki Mukai
Tiffini Voss
James Kost
Julie Stone
Christine Furtek
Erin Mahoney
Jeffrey L. Cummings
Pierre N. Tariot
Paul S. Aisen
Bruno Vellas
Christopher Lines
David Michelson
机构
[1] Merck & Co.,University of Nevada Las Vegas Department of Brain Health
[2] Inc.,Gerontopole, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center
[3] Cleveland Clinic Lou Ruvo Center for Brain Health,undefined
[4] Banner Alzheimer’s Institute,undefined
[5] University of Southern California,undefined
[6] Toulouse University Hospital,undefined
[7] Merck & Co.,undefined
[8] Inc.,undefined
[9] UG 4C-06,undefined
来源
Alzheimer's Research & Therapy | / 11卷
关键词
Verubecestat; BACE inhibitor; Amyloid; Alzheimer’s disease; Clinical trial; Safety;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 186 条
[1]  
Masters CL(2015)Alzheimer’s disease Nat Rev Dis Primers 1 505-517
[2]  
Bateman R(2016)Alzheimer’s disease Lancet. 388 595-608
[3]  
Blennow K(2016)The amyloid hypothesis of Alzheimer’s disease at 25 years EMBO Mol Med 8 319-329
[4]  
Rowe CC(2014)Targeting the beta secretase BACE1 for Alzheimer’s disease therapy Lancet Neurol 13 1430-1440
[5]  
Sperling RA(2012)Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease Arch Neurol 69 341-350
[6]  
Cummings JL(2013)A phase 3 trial of semagacestat for treatment of Alzheimer’s disease N Engl J Med 369 311-321
[7]  
Scheltens P(2014)Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease N Engl J Med 370 322-333
[8]  
Blennow K(2014)Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease N Engl J Med 370 50-56
[9]  
Breteler MM(2016)The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Nature 537 4-28
[10]  
de Strooper B(2014)Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects J Neurochem 130 158-169